CD274 and esophageal squamous cell carcinoma: This ORR is higher than that reported for pembrolizumab monotherapy in the KEYNOTE-181 trial (22% in PD-L1 CPS ≥10 East Asian patients) or nivolumab monotherapy in ATTRACTION-3 (19.3%) for previously treated ESCC (17–19).